Table 5 Adverse events in cancer and noncancer patients

Death

8 (4)

4 (5)

4 (2)

VTE

0 (0)

0 (0)

0 (0)

Cancer progression

4 (2)

4 (5)

NA

Pneumonia

2 (1)

0 (0)

2 (1)

Interstitial pneumonia

2 (1)

0 (0)

2 (1)

VTE recurrence

4 (2)

2 (2)

2 (1)

PE

1 (1)

0 (0)

1 (1)

DVT

3 (1)

2 (2)

1 (1)

Major bleeding

5 (2)

2 (2)

3 (2)

Intracranial hemorrhage

1 (1)

0 (0)

1 (1)

Muscular hemorrhage

1 (1)

0 (0)

1 (1)

Retroperitoneal hemorrhage

1 (1)

1 (1)

0 (0)

Gastrointestinal bleeding

2 (1)

1 (1)

1 (1)

Clinically relevant nonmajor bleeding

6 (3)

2 (2)

4 (3)

Discontinuation of edoxaban

20 (9)

10 (12)

10 (7)